Cas:6277-26-5 Acetone Benzothiazolyl-2-hydrazone manufacturer & supplier

Chemical Name:Acetone Benzothiazolyl-2-hydrazone

CAS.NO:6277-26-5

Synonyms:acetone-benzothiazolyl-2-hydrazone

Molecular Formula:C₁₀H₁₁N₃S

Molecular Weight:205.27900

HS Code:

Physical and Chemical Properties:

Melting point:198ºC

Boiling point:321ºC at 760 mmHg

Density:1.25g/cm3

Index of Refraction:1.657

PSA:65.52000

Exact Mass:205.06700

LogP:3.17700

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like acetone-benzothiazolyl-2-hydrazone chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,acetone-benzothiazolyl-2-hydrazone physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,acetone-benzothiazolyl-2-hydrazone Use and application,acetone-benzothiazolyl-2-hydrazone technical grade,usp/ep/jp grade.

Related News: Trial results demonstrated that Oligomannate statistically improved cognitive function in mild-to-moderate AD patients as early as week 4 and the benefit was sustained at each follow-up assessment visit,�� Shanghai Green Valley Pharmaceuticals, which developed the drug along with two academic institutions in China, said in a statement. Acetone Benzothiazolyl-2-hydrazone manufacturer Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,�� said Mark Corbett, EVP, Inceptua Medicines Access. Acetone Benzothiazolyl-2-hydrazone supplier Advanced clinical trials with the Company��s lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS. Acetone Benzothiazolyl-2-hydrazone vendor This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.? Acetone Benzothiazolyl-2-hydrazone factory In a statement to Fierce Medtech, Innova said it has completed some corrective actions, while others are still underway, and that the U.S. recall was launched to reclaim tests distributed to employees, clinical studies and to customers for early evaluation. The company said it plans to seek an emergency use authorization and comply with all FDA requirements.